Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1985 1
1987 1
1988 2
1989 2
1991 3
1993 1
1995 4
1996 3
1997 5
1998 4
1999 7
2000 11
2001 15
2002 7
2003 4
2004 4
2005 5
2006 8
2007 6
2008 6
2009 12
2010 14
2011 9
2012 10
2013 12
2014 15
2015 24
2016 22
2017 30
2018 34
2019 29
2020 36
2021 31
2022 32
2023 40
2024 40
2025 31

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

452 results

Results by year

Filters applied: . Clear all
Page 1
Ide-cel vs standard regimens in triple-class-exposed relapsed and refractory multiple myeloma: updated KarMMa-3 analyses.
Ailawadhi S, Arnulf B, Patel K, Cavo M, Nooka AK, Manier S, Callander N, Costa LJ, Vij R, Bahlis NJ, Moreau P, Solomon S, Abrahamsen IW, Baz R, Broijl A, Chen C, Jagannath S, Raje N, Scheid C, Delforge M, Benjamin R, Pabst T, Iida S, Berdeja J, Giralt S, Truppel-Hartmann A, Chen Y, Zhong X, Wu F, Piasecki J, Eliason L, Dhanda D, Felten J, Caia A, Cook M, Popa McKiver M, Rodríguez-Otero P. Ailawadhi S, et al. Among authors: pabst t. Blood. 2024 Dec 5;144(23):2389-2401. doi: 10.1182/blood.2024024582. Blood. 2024. PMID: 39197072 Clinical Trial.
Molecular Minimal Residual Disease in Acute Myeloid Leukemia.
Jongen-Lavrencic M, Grob T, Hanekamp D, Kavelaars FG, Al Hinai A, Zeilemaker A, Erpelinck-Verschueren CAJ, Gradowska PL, Meijer R, Cloos J, Biemond BJ, Graux C, van Marwijk Kooy M, Manz MG, Pabst T, Passweg JR, Havelange V, Ossenkoppele GJ, Sanders MA, Schuurhuis GJ, Löwenberg B, Valk PJM. Jongen-Lavrencic M, et al. Among authors: pabst t. N Engl J Med. 2018 Mar 29;378(13):1189-1199. doi: 10.1056/NEJMoa1716863. N Engl J Med. 2018. PMID: 29601269 Free article.
Outcomes of bispecific antibody therapy after CAR T-cell failure in relapsed/refractory large B-cell lymphoma.
Shumilov E, Scholz JK, Seib M, Mazzeo P, Wurm-Kuczera R, Vucinic V, Holtick U, Boyadzhiev H, Melchardt T, Hölscher A, Schultze-Florey C, Abdelhafez A, Velazquez GF, Ossami Saidy A, Lesan V, Schnetzke U, Kerkhoff A, Bacher U, Ghandili S, Aydilek E, Gebauer N, Weber T, Wulf G, Glass B, Thurner L, Heidel FH, Schmid C, Viardot A, Hänel M, Dietrich S, Pabst T, Ayuk F, von Tresckow B, Chapuy B, Pott C, Müller F, Lenz G. Shumilov E, et al. Among authors: pabst t. Blood Adv. 2025 Aug 12;9(15):3955-3966. doi: 10.1182/bloodadvances.2024015719. Blood Adv. 2025. PMID: 40238938 Free PMC article.
Boosting CAR T cells against lymphomas.
Pabst T, Bacher U. Pabst T, et al. Blood. 2024 Aug 15;144(7):689-691. doi: 10.1182/blood.2024025378. Blood. 2024. PMID: 39145947 Free article. No abstract available.
Bispecific antibodies targeting BCMA or GPRC5D are highly effective in relapsed myeloma after CAR T-cell therapy.
Merz M, Dima D, Hashmi H, Ahmed N, Stölzel F, Holderried TAW, Fenk R, Müller F, Tovar N, Oliver-Cáldes A, Rathje K, Davis JA, Fandrei D, Vucinic V, Kharboutli S, Baermann BN, Ayuk F, Platzbecker U, Albici AM, Schub N, Schmitz F, Shune L, Khouri J, Anwer F, Raza S, McGuirk J, Mahmoudjafari Z, Green K, Khandanpour C, Teichert M, Jeker B, Hoffmann M, Kröger N, von Tresckow B, de Larrea CF, Pabst T, Abdallah AO, Gagelmann N. Merz M, et al. Among authors: pabst t. Blood Cancer J. 2024 Dec 5;14(1):214. doi: 10.1038/s41408-024-01197-2. Blood Cancer J. 2024. PMID: 39632797 Free PMC article.
Molecular characterization of mutant TP53 acute myeloid leukemia and high-risk myelodysplastic syndrome.
Grob T, Al Hinai ASA, Sanders MA, Kavelaars FG, Rijken M, Gradowska PL, Biemond BJ, Breems DA, Maertens J, van Marwijk Kooy M, Pabst T, de Weerdt O, Ossenkoppele GJ, van de Loosdrecht AA, Huls GA, Cornelissen JJ, Beverloo HB, Löwenberg B, Jongen-Lavrencic M, Valk PJM. Grob T, et al. Among authors: pabst t. Blood. 2022 Apr 14;139(15):2347-2354. doi: 10.1182/blood.2021014472. Blood. 2022. PMID: 35108372 Free PMC article.
Intensified Therapy of Acute Lymphoblastic Leukemia in Adults: Report of the Randomized GRAALL-2005 Clinical Trial.
Huguet F, Chevret S, Leguay T, Thomas X, Boissel N, Escoffre-Barbe M, Chevallier P, Hunault M, Vey N, Bonmati C, Lepretre S, Marolleau JP, Pabst T, Rousselot P, Buzyn A, Cahn JY, Lhéritier V, Béné MC, Asnafi V, Delabesse E, Macintyre E, Chalandon Y, Ifrah N, Dombret H; Group of Research on Adult ALL (GRAALL). Huguet F, et al. Among authors: pabst t. J Clin Oncol. 2018 Aug 20;36(24):2514-2523. doi: 10.1200/JCO.2017.76.8192. Epub 2018 Jun 4. J Clin Oncol. 2018. PMID: 29863974 Free article. Clinical Trial.
Fitness assessment in acute myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet.
Venditti A, Palmieri R, Maurillo L, Röllig C, Wierzbowska A, de Leeuw D, Efficace F, Curti A, Ngai LL, Tettero J, Adès L, Almeida A, Bullinger L, Dennis M, Esteve J, Ferrara F, Heuser M, Huls G, Lübbert M, Mehta P, Montesinos P, Pabst T, Récher C, Rossi G, Russell N, Sierra J, Stauder R, Vey N, Walter RB, Wang E, Nier S, Martins CG, Ossenkoppele G. Venditti A, et al. Among authors: pabst t. Blood Adv. 2025 May 13;9(9):2207-2220. doi: 10.1182/bloodadvances.2024013744. Blood Adv. 2025. PMID: 39913928 Free PMC article. Review.
Safety and efficacy of glofitamab for relapsed/refractory large B-cell lymphoma in a multinational real-world study.
Shumilov E, Wurm-Kuczera R, Kerkhoff A, Wang M, Melchardt T, Holtick U, Bacher U, Staber P, Mazzeo P, Leng C, Böckle D, Hölscher A, Kauer J, Rotter N, Vucinic V, Rudzki J, Nachbaur D, Bücklein V, Schnetzke U, Krämer I, Wille K, Hasse A, von Tresckow B, Hänel M, Koenecke C, Velazquez GF, Viardot A, Schmid C, Thurner L, Wolf D, Subklewe M, Dreyling M, Dreger P, Dietrich S, Keller U, Jäger U, Greil R, Pabst T, Lenz G, Chapuy B. Shumilov E, et al. Among authors: pabst t. Blood Adv. 2025 Aug 12;9(15):3865-3877. doi: 10.1182/bloodadvances.2024014903. Blood Adv. 2025. PMID: 39661985 Free PMC article.
452 results